Drug Safety
My favorite three presentations from day 4 (Tuesday) at ACR 2021 included the following.
swethaann23 swethaann23
3 years 7 months ago
Retrospective chart review of rheumatic irAE patients:
Persistent rheumatic irAE activity 🔼received GC
Inflammatory arthritis pts 🔼risk of persistent rheumatic irAE
Risk factors for mortality➡️tumor progression➕ continued Rx GC at last follow-up
Abst#1516 #ACR21 @RheumNow https://t.co/KusNaVlEXp
Akhil Sood MD AkhilSoodMD
3 years 7 months ago
Abst 1517
Weinmann & colleagues studied prevalence of autoantibodies in Melanoma pts treated w/ ICI & developed rheumatic IRAE
- Most common rheumatic IRAE = inflammatory arthritis
- Higher prevalence of ANA in those tx w/ chemo prior to ICI
#ACR21 @RheumNow https://t.co/7qgogSMjUr
Hitting the home stretch, day 3 presentations were big! Here are a few of my favorites: secukinumab efficacy in juvenile PsA; VEXAS - predicting poor outcomes; and the FDA Safety Update session.
Should we start considering therapeutic drug monitoring when prescribing TNFi for treatment of our rheumatologic conditions?
Eric Dein ericdeinmd
3 years 7 months ago
#ACR21 Ab#1941: ORAL Surveillance VTE risk
▶️Tofa 10 BID risk > 5 BID > TNFi for VTE, DVT, PE
▶️Age, male, obesity, HTN, h/o VTE, oral contraception/HRT, steroids, antidepressants were risk factors
@RheumNow
https://t.co/JOKNyYVZfX https://t.co/mTkgkwPIT6
Eric Dein ericdeinmd
3 years 7 months ago
#ACR21 Ab#1939: Tofa CV Outcome (STAR-RA)
▶️Pooled data does not show ⬆️ risk of CVD
▶️Trend in pts w prior CVD -HR 1.27 (0.95-1.7), cannot r/o CVD risk in pts w risk factors
Less clear than oral surveillance data, but concerns in those w risks
https://t.co/JOKNyYVZfX @Rheumnow https://t.co/GGYJfxcqhc
Richard Conway RichardPAConway
3 years 7 months ago
ORAL Surveillance malignancy risk @RADoctor . Numerically higher at both doses tofacitinib compared to TNFi . Abstr#1940 #ACR21 @RheumNow https://t.co/uc2k5EaiRq
David Liew drdavidliew
3 years 7 months ago
STAR-RA, CV risk
large insurance datax3
tofa vs TNFi
all comers: HR 1.01 (0.83-1.23)
one CV RF + any MTX: HR 1.24 (0.90-1.69)
prev CVD: HR 1.27 (0.95-1.70)
not sig
but surely okay to say baseline CV risk + tofa makes me a little nervous?
@SeoyoungCKim #ACR21 ABST1939 @RheumNow https://t.co/LmmL5zgv9u
Poster Hall